NV-NTT
The city of Las Vegas and NTT Corporation (NTT) today announced the Accelerate Smart project has expanded to include two new locations – the city’s Community Healing Garden and a portion of Las Vegas Boulevard at South Main Street and East St. Louis Avenue. As part of the partnership, NTT and the city plan to further expand the smart cities project to Bob Baskin Park, Rotary Park, Stupak Park and Ethel Pearson Park this summer before adding six additional parks by the end of 2020.
Following the success of the initial pilot , which has improved traffic congestion and wrong way driving, NTT will expand the project to provide real-time alerts of safety conditions and maintenance issues to improve public safety and provide a better experience for citizens and visitors. The city’s Smart Park Initiative is designed to increase public safety, while providing awareness of activity to generate usage and operations benchmarks that allow leadership to make more informed decisions.
In total, high-definition optical and audio sensors will now be deployed at 14 locations across the city, which enable an automated system to notify law enforcement and maintenance personnel of safety hazards, such as large crowds, gunshots, breaking glass and vandalism.
“Cities that learn, understand and invest in technology will be the cities of the future, and Las Vegas is at the forefront of innovation,” said Michael Sherwood, Director of Innovation and Technology, city of Las Vegas. “Our Smart Cities pilot has been such a success that we are excited to expand the program to several new locations in the heart of our city, which will continue to improve the lives of our residents and visitors.”
The initial proof of concept provided information to city personnel to increase situational awareness and provide a foundation for traffic management. With the expansion of the smart cities project, Las Vegas will leverage a dashboard to access and view sensors, data streams and analytics. The timely alerts and predictions enable the city to monitor and review events and allow them to dispatch safety and maintenance personnel in a timely manner.
The NTT Accelerate Smart data platform is a secure, distributed platform that captures data via sensors and micro data centers in the designated areas through video and sound, while also integrating historical data sources such as crime, weather and social media. By leveraging cognitive analytics, including machine learning technologies, the system learns normal patterns and can detect and alert authorities of patterns that appear abnormal.
“As we accelerate our smart cities project in Las Vegas, it demonstrates how a more connected society directly benefits citizens,” said Bill Baver, Go to Market Leader, Smart World Team, NTT. “Cities like Las Vegas are capitalizing on successful pilots and beginning to imagine the benefits these technologies can have for their residents and visitors. However, smart is not confined to city limits, as it also extends to stadiums, shopping malls and manufacturing facilities by leveraging similar concepts that have been proven successful in Las Vegas.”
The Accelerate Smart solution deployed in Las Vegas is built on NTT’s innovative Cognitive Foundation™ architecture, which enables remote creation, management and operation of information and communications technology resources, from devices and networks to the cloud. It also incorporates hyperconverged infrastructure and IoT gateways, as well as virtualization software hosting predictive analytics applications.
The partnership with NTT is part of the city of Las Vegas’ charter in becoming a smart city to provide safe, reliable and efficient civic technology that stimulates economic growth. To learn more about the Smart Cities initiative in Las Vegas, visit NTT’s website and watch the case study on YouTube .
About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
For more information on NTT, visit www.global.ntt/
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005261/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom